And so I think we feel bullish there. And when we look at what we see in terms of initial implant growth and the distribution of that implant growth, what we see in terms of DIXI and the DIXI growth that we’ve been seeing, and then when you combine that with now the pilot starting in CARE, the product launches that we’ve had with nSight as well as the tablet that are going to help us scale with efficiency. We really feel like from a product and market perspective, we are really well-positioned for the rest of ’23 as well as into ’24. And something that I haven’t mentioned. On top of all of those things, we’ve made a lot of progress here with a number of things we’ve been working on internally, including sales leadership, structure and the direct line of sight that gives us to execution, some changes we’ve made there.
We are also working on and assessing our sales compensation structure to ensure that we’re properly set up here to really consistent growth in the business. And so I think we feel really good about pipeline as well as the way where we’re positioned for execution here, both with markets and products in our own organization.
Unidentified Analyst: Great. Thank you. Another follow-up. It sounds like growth is coming primarily from growing utilization in existing accounts. So if that’s the case, how should we be thinking about the trajectory of new center adds? And where do you think penetration stands within the total center opportunity? Thanks so much.
Joel Becker: Yes, it’s a great question. And we, of course, continue to look to add additional centers, but we’ve got a strong penetration across the Level 4 centers in most cases today. So our focus has really been expanding adoption within the centers and expanding utilization within current customers. So that’s where our focus has been, and where we are seeing most of the growth come from is expanding adoption and utilization within that core group of centers versus necessarily needing to add a lot of additional Level 4 centers given the penetration that we have within those groups.
Unidentified Analyst: Great. Thank you.
Joel Becker: Thank you.
Operator: Thank you. As there are no further questions, I would now hand the conference over to Joel Becker, CEO, for closing comments.
Joel Becker: Thank you. Yes, I would just — thanks, everybody for being on the call today. Thanks for the questions. I would just close with another really good strong quarter here with the year-on-year revenue growth of 47%, increasing guidance with the range going up from $62.5 million to $63.5 million from $59 million to $61 million where we were. Again, consistent revenue performance coming off an all-time high for the company with OpEx control and cash management and some good operating execution on a number of core initiatives as well. I think with both the near-term initiatives of our penetration within the Level 4 centers, the expansion opportunities with DIXI and the recent product launches we’ve had, the way the CARE expansion is setting up for us with initial implants started and the pilot here in the first half and the sense of urgency and level of focus that we’ve got on execution within the business.
On top of all that, being on track with our NAUTILUS enrollment completing in Q1 and expanding this into the [ IgE ] population, we feel like we’re really well positioned here for the rest of ’23 and into ’24 to take advantage of increasing RNS access into the 1.2 million patients that are drug-resistant in the United States today. Our target market is 30,000 patients. So 50,000 a year in Level 4 centers in the focal population inside of that. And here with the actions that we are talking about with the direction of the business and the strategy that we are taking in a short period of time with these activities, we’re positioning ourselves to expand from that 30,000 to the 1.2 million of drug resistant population of patients in the U.S. So again, I think we are really well-positioned and we are really focused on consistent demonstration of execution that show how we are moving on that strategy.
So I appreciate everybody being part of the call today, and thanks for your time.
Operator: Thank you. The conference of NeuroPace, Inc. has now concluded. Thank you for your participation. You may now disconnect your lines.
